Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Affiris AG
AFFITOPE AD02 is a second generation AD immunotherapeutics targeting Aβ. Its active component is a synthetic peptide functionally mimicking the unmodified N-terminus of Aβ.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent capability
Early AD, based on episodic memory deficit and hippocampal atrophy
Age from 50 to 80, inclusive
MMSE of 20+
Brain magnetic resonance imaging scan consistent with the diagnosis of AD
Stable doses of medications (cholinesterase inhibitors and memantine allowed)
Caregiver able to attend all visits with patient
You may not be if
Significant neurological disease other than AD
Major psychiatric illness
Significant systemic illness
Autoimmune disease
Prior treatment with experimental immunotherapeutics for AD including IVIG
Women of childbearing potential without birth control
